Jiamin Du

Dr. Jiamin Du

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Open access
JDJiamin Du
Jiamin Du
SJSarah Janus
Sarah Janus
BVBrenda Voorthuis
Brenda Voorthuis
JMJeannette van Manen
Jeannette van Manen
WAWilco Achterberg
Wilco Achterberg
SZSytse Zuidema
Sytse Zuidema
Objective: Several European studies investigated the trends in psychotropic drug prescriptions (PDPs) among nursing home (NH) residents and reported a decline in antipsychotics prescriptions. Since the Dutch long‐term care system differs from other European systems (e.g. higher threshold for NH admission and trained elderly care physicians), this study explores the trends in PDPs in Dutch NH residents with dementia.Methods: The study used data from nine studies, comprising two cross‐sectional studies, one cohort study, and six cluster‐randomized controlled trials, collected in Dutch NHs between 2003 and 2018. With multilevel logistic regression analysis, NHs as a random effect, we estimated the trends in PDPs overall and for five specific psychotropic drug groups (antipsychotics, antidepressants, anxiolytics, hypnotics, and anti‐dementia drugs), adjusting for confounders: age, gender, severity of dementia, severity of neuropsychiatric symptoms, and length of stay in NHs.Results: The absolute prescription rate of antipsychotics was 37.5% in 2003 and decreased (OR = 0.947, 95% CI [0.926, 0.970]) every year. The absolute prescription rate of anti‐dementia drugs was 0.8% in 2003 and increased (OR = 1.162, 95% CI [1.105, 1.223]) per year. The absolute rate of overall PDPs declined from 62.7% in 2003 to 40.4% in 2018.Conclusions: Among Dutch NH residents with dementia, the odds of antipsychotics prescriptions decreased by 5.3% per year while the odds of anti‐dementia drug prescriptions increased by 16.2%. There were no distinct trends in antidepressants, anxiolytics, and hypnotics prescriptions. However, overall PDPs were still high. The PDPs in NH residents remain an issue of concern.

YZYing Zou
Ying Zou
SJSarah Janus
Sarah Janus
JDJiamin Du
Jiamin Du
NQNing Qu
Ning Qu
KZKarel Tsjalling Zuidema
Karel Tsjalling Zuidema
SZSytse Zuidema
Sytse Zuidema
Background: Although effective and recommended by guidelines worldwide, Cardiac Rehabilitation (CR) remains scarce and underutilized. CR implementation has taken place in middle-income countries, but the progress is influenced by both positive and negative factors that remain underexplored. This study identified the barriers and facilitators of CR in a middle-income country, specifically China. Methods: An exploratory qualitative study was conducted using semi-structured interviews. Results: Fifteen CR stakeholders were interviewed. According to the interviewees, the delivery of CR is impeded due to a lack of resources, a lack of CR professionals, and a lack of coordination between health institutions. The participation of CR is hindered by a lack of awareness, a lack of reimbursement, and a lack of access to CR. However, the interviewees also mentioned facilitating factors, namely, a positive attitude of stakeholders, high motivation of some patients, and policy support. Conclusions: More awareness regarding the effectiveness of CR is needed. Implementing CR in secondary and primary health institutions could overcome the barriers regarding travel distance and transportation to faraway hospitals. The CR reimbursement methods are needed to ease the financial burden on patients. Our findings reveal factors that need to be considered by policymakers to deliver CR on a wider scale in China.

30 January 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
YZYing Zou
Ying Zou
JDJiamin Du
Jiamin Du
Huibert BurgerHuibert Burger
Huibert Burger
SZSytse Zuidema
Sytse Zuidema
SWSjoukje van der Werf
Sjoukje van der Werf
NQNing Qu
Ning Qu
Aims: Traditional centre-based cardiac rehabilitation (CBCR) has several drawbacks, including high costs, limited accessibility, and low utilisation rates. As a result, alternative cardiac rehabilitation programmes (ACRPs), such as home-based rehabilitation and telerehabilitation, have been developed. This systematic review aims to synthesise existing evidence on the economic evaluation of ACRPs compared to CBCR. Methods and results: We searched databases of MEDLINE, Embase, CINAHL, Cochrane CENTRAL, Web of Science, and EconLit, as well as trials registers of Clinicaltrials.gov, International Clinical Trials Registry Platform, and EU Clinical Trials Register. The last search date was 20 March 2025. We included randomised controlled trials that directly compared ACRP with CBCR in terms of cost and effectiveness. Study quality was assessed using the Cochrane Risk of Bias tool and the Drummond 10-item checklist. Both qualitative and quantitative syntheses were conducted, with random-effects models applied in the meta-analysis. Thirteen studies met the inclusion criteria, comprising 2040 participants. Meta-analysis showed a non-significant trend favouring CBCR over ACRP for EQ-5D (SMD = −0.32; 95% CI: −0.71 to 0.06; I2 = 79%). For QALY, there was no difference between ACRP and CBCR (SMD = −0.02; 95% CI: −0.19 to 0.15; I2 = 0). Ten of the thirteen studies reported lower costs for ACRP compared with traditional CBCR. Three of five economic evaluations found ACRP to be cost-effective. Conclusion: ACRPs demonstrate cost-effectiveness comparable to traditional CBCR. This review highlights the potential of ACRPs, such as home-based rehabilitation and telerehabilitation, as solutions for broader implementation in CR practice.


1 July 2026 in medRxiv
Verified
Preprint
Open access
BLBethany Linder
Bethany Linder
JDJiamin Du
Jiamin Du
NTNuno Tavares
Nuno Tavares
TZTingting Zhu
Tingting Zhu
Prayag TiwariPrayag Tiwari
Prayag Tiwari
JGJaheeda Gangannagaripalli
Jaheeda Gangannagaripalli
Background: Polypharmacy is common in people living with dementia (PLwD) and associated with adverse outcomes. Although Structured Medication Reviews (SMRs) are recommended to optimise medication regimens, their delivery is often constrained by limited healthcare resources. Artificial intelligence (AI) may support SMRs, yet little is known about how it is perceived by PLwD and their carers. This study explored their experiences of polypharmacy, views on SMRs, and attitudes towards use of AI tools in SMRs. Methods: Semi-structured interviews with 12 PLwD experiencing polypharmacy and two focus groups with 14 carers were conducted via Microsoft Teams or telephone and analysed using Reflexive Thematic Analysis. Results: Two themes were constructed: experiences of SMRs, and attitudes towards AI in SMRs. Participants described challenges in managing polypharmacy, with carers often playing a central role in supporting adherence and monitoring side effects. Experiences of SMRs varied widely. SMRs were most valued when clinicians were empathetic and able to offer personalised guidance. Participants viewed AI use in SMRs positively, provided that such tools were well validated and used to assist rather than replace healthcare professionals. AI was viewed as having the potential to reduce administrative burden and support more person-centred care. However, some had concerns regarding patient safety and data security, highlighting the need for appropriate regulation and human oversight. Conclusion: Participants were supportive of AI use in SMRs, despite concerns about safety, data security and disclosure of AI use, and emphasised the importance of patient–clinician interactions and lived experience involvement in AI tool development.

25 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
JDJiamin Du
Jiamin Du
COChelsea Owens
Chelsea Owens
EGEmily Giles
Emily Giles
UKUrmila Keswani
Urmila Keswani
GGGrace Gillis
Grace Gillis
LMLola Martos
Lola Martos
Background: The Oxford Brain Health Clinic (OBHC) was launched in August 2020 to provide enhanced assessments for memory clinic patients including MRI, advanced cognitive and lifestyle assessments, and optional research assessments. This study evaluates the impact of the OBHC pathway on psychiatrists' diagnostic confidence and the perceived usefulness of each assessment compared to a standard memory clinic (MC) pathway, to inform future refinement and NHS adoption. Method: We retrospectively selected 100 cases from the South Oxford memory clinic (50 OBHC, 50 MC) seen between August 2021 and August 2022. Anonymised records, including assessments, diagnoses, and management plans, were extracted and reviewed. Six psychiatrists rated their diagnostic confidence (0 = no confidence, 10 = no doubt) and the usefulness of each assessment using a five‐point Likert scale (range from 1 = not useful at all to 5 = extremely useful). Each case was randomly assigned to two raters. Descriptive analysis was conducted for confidence and usefulness scores. Mann‐Whitney U tests were used to compare diagnostic confidence between pathways, and multiple linear regression was applied to adjust for the influence of patients' cognitive status. Results: In the OBHC pathway, 48% of cases had dementia, 24% had mild cognitive impairment (MCI), and 28% had no memory disorder related diagnosis, compared to 74%, 16%, and 10% respectively in the MC pathway. Mean diagnostic confidence was high in both pathways (OBHC:8.58 ± 1.2; MC:8.38 ± 1.2). Regression analysis indicated that the OBHC pathway resulted in higher diagnostic confidence (β = ‐0.521, p = 0.067) compared to the MC pathway, although the result was not statistically significant. Assessments rated as useful (scores > 3) in the OBHC pathway included MRI, ACE‐III, observations, and informant interviews, while the MC pathway prioritised clinical interviews, relative discussions, CT, and MoCA. Conclusions: The OBHC pathway demonstrates diagnostic confidence equal to or greater than that of standard memory clinics and offers all patients research engagement opportunities. Some assessments within the OBHC pathway address dementia risk factors, potentially enhancing management and research initiatives despite their limited immediate diagnostic utility. These results support the further refinement of the OBHC pathway within the NHS.